Doctors track lung cancer Drug's Real-World performance in korean patients
NCT ID NCT04592523
Summary
This study is monitoring the safety and effectiveness of the lung cancer drug brigatinib in real-world hospital settings in South Korea. Researchers will follow about 257 adults with a specific type of advanced lung cancer (ALK-positive NSCLC) who are starting brigatinib treatment for the first time. The main goal is to track all side effects and see how well the drug controls the cancer over two years of observation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL -CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pusan National University Hospital
RECRUITINGBusan, 49241, South Korea
Conditions
Explore the condition pages connected to this study.